{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:29:10Z","timestamp":1788449350353,"version":"build-2803163510"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Low-grade, low-stage endometrioid carcinomas (LGLS EC) demonstrate 5-yr survival rates up to 95%. However, a small subset of these tumors recur, and little is known about prognostic markers or established mutation profiles associated with recurrence. The goal of the current study was to identify the molecular profiles of the primary carcinomas and the genomic differences between primary tumors and subsequent recurrences. Four cases of LGLS EC with recurrence and 8 cases without recurrence were evaluated via whole-exome sequencing. Three of the 4 recurrent tumors were evaluated via Oncomine Comprehensive Assay. The resulting molecular profiles of the primary and recurrent tumors were compared. Two of the 3 recurrent cases showed additional mutations in the recurrence. One recurrent tumor included an additional <jats:italic toggle=\"yes\">TP53<\/jats:italic> mutation and the other recurrent tumor showed <jats:italic toggle=\"yes\">POLE<\/jats:italic> and <jats:italic toggle=\"yes\">DDR2<\/jats:italic> kinase gene mutation. The <jats:italic toggle=\"yes\">POLE<\/jats:italic> mutation occurred outside the exonuclease domain. <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic> mutations were detected in 4 of 4 primary LGLS EC with recurrence and in 3 of 8 disease-free cases. LGLS EC with recurrence showed higher MSIsensor scores compared with LGLS without recurrence. The level of copy number gains in LGLS EC with recurrence was larger than LGLS EC without recurrence. This pilot study showed 1 of 3 recurrent cases gained a mutation associated with genetic instability (<jats:italic toggle=\"yes\">TP53<\/jats:italic>) and 1 of them also acquired a mutation in the DDR2 kinase, a potential therapeutic target. We also noted a higher level of copy number gains, MSIsensor scores and <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic> mutations in the primary tumors that later recurred.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000798","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T15:02:20Z","timestamp":1630940540000},"page":"207-219","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence"],"prefix":"10.1097","volume":"41","author":[{"given":"Cathleen E.","family":"Matrai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Wha","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeshna","family":"Chatterjee-Paer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Motanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Mirabelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Kurtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Sigaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Chapman-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Holcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sboner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora Hedrick","family":"Ellenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"R1-20250802","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"R4-20250802","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/cncr.30094","article-title":"Endometrial cancer: not your grandmother\u2019s cancer","volume":"122","author":"McAlpine","year":"2016","journal-title":"Cancer"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.radonc.2015.11.013","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"117","author":"Colombo","year":"2015","journal-title":"Radiother Oncol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(09)62002-X","article-title":"Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis","volume":"375","author":"Todo","year":"2010","journal-title":"Lancet"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2015.35","article-title":"Just how accurate are the major risk stratification systems for early-stage endometrial cancer?","volume":"112","author":"Bendifallah","year":"2015","journal-title":"Br J Cancer"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/14737140.2015.992420","article-title":"Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping","volume":"15","author":"Liu","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Getz","year":"2013","journal-title":"Nature"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40661-016-0035-4","article-title":"New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care","volume":"3","author":"Talhouk","year":"2016","journal-title":"Gynecol Oncol Res Pract"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Biology of human tumors improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer\u2014combined analysis of the PORTEC Cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ygyno.2019.03.100","article-title":"Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers","volume":"153","author":"Moroney","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2014.06.010","article-title":"\u03b2-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers","volume":"134","author":"Myers","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod Pathol"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"dju245","DOI":"10.1093\/jnci\/dju245","article-title":"Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma","volume":"106","author":"Liu","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"7935","DOI":"10.18632\/oncotarget.13854","article-title":"Prognostic role of NF-YA splicing isoforms and Lamin A status in low grade endometrial cancer","volume":"8","author":"Cicchillitti","year":"2017","journal-title":"Oncotarget"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ygyno.2017.10.025","article-title":"Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions","volume":"148","author":"Fonnes","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13000-017-0668-6","article-title":"p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry","volume":"12","author":"Fadare","year":"2017","journal-title":"Diagn Pathol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamaoncol.2015.1313","article-title":"Whole-exome sequencing of metastatic cancer and biomarkers of treatment response","volume":"1","author":"Beltran","year":"2015","journal-title":"JAMA Oncol"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"16019","DOI":"10.1038\/npjgenmed.2016.19","article-title":"Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care","volume":"1","author":"Rennert","year":"2016","journal-title":"NPJ Genomic Med"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","article-title":"MSIsensor: microsatellite instability detection using paired tumor-normal sequence data","volume":"30","author":"Niu","year":"2014","journal-title":"Bioinformatics"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/s41379-020-0552-x","article-title":"Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity","volume":"33","author":"Ginter","year":"2020","journal-title":"Mod Pathol"},{"key":"R31-20250802","first-page":"432","article-title":"Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas","volume":"15","author":"Jiang","year":"2014","journal-title":"Genome Biol"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biostatistics\/kxh008","article-title":"Circular binary segmentation for the analysis of array-based DNA copy number data","volume":"5","author":"Olshen","year":"2004","journal-title":"Biostatistics"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/2159-8274.CD-11-0005","article-title":"Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer","volume":"1","author":"Hammerman","year":"2011","journal-title":"Cancer Discov"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s13059-014-0439-6","article-title":"Unraveling the clonal hierarchy of somatic genomic aberrations","volume":"15","author":"Prandi","year":"2014","journal-title":"Genome Biol"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat Methods"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.1073\/pnas.1411446111","article-title":"Copy number alteration burden predicts prostate cancer relapse","volume":"111","author":"Hieronymus","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 1","key":"R37-20250802","first-page":"S105","article-title":"Carcinoma of the Corpus Uteri","volume":"95","author":"Creasman","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"eaav2437","DOI":"10.1126\/sciadv.aav2437","article-title":"Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy","volume":"5","author":"Tu","year":"2019","journal-title":"Sci Adv"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-015-2047-z","article-title":"Evaluation of chromosome 1q gain in intracranial ependymomas","volume":"127","author":"Rajeshwari","year":"2016","journal-title":"J Neurooncol"},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","article-title":"Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation","volume":"58","author":"Shah","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"R41-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"key":"R43-20250802","first-page":"1053","article-title":"Getting a clue from 1q: gain of chromosome 1q in cancer","volume":"2","author":"Puri","year":"2014","journal-title":"J Cancer Biol Res"},{"key":"R44-20250802","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1158\/1078-0432.CCR-17-0566","article-title":"Amplification of 1q32.1 refines the molecular classification of endometrial carcinoma","volume":"23","author":"Depreeuw","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R45-20250802","first-page":"207","article-title":"The effect of first chromosome long arm duplication on survival of endometrial carcinoma","volume":"11","author":"Sever","year":"2014","journal-title":"Turk J Obstet Gynecol"},{"key":"R46-20250802","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13000-019-0847-8","article-title":"Mesonephric adenocarcinoma of the cervix: a case report with a three-year follow-up, lung metastases, and next-generation sequencing analysis","volume":"14","author":"Montalvo","year":"2019","journal-title":"Diagn Pathol"},{"key":"R47-20250802","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PGP.0000000000000306","article-title":"Mixed mesonephric adenocarcinoma and high-grade neuroendocrine carcinoma of the uterine cervix: case description of a previously unreported entity with insights into its molecular pathogenesis","volume":"36","author":"Cavalcanti","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R48-20250802","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/modpathol.2015.103","article-title":"Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract","volume":"28","author":"Mirkovic","year":"2015","journal-title":"Mod Pathol"},{"key":"R49-20250802","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"R50-20250802","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod Pathol"},{"key":"R51-20250802","first-page":"402","article-title":"Prognostic significance of POLE proofreading mutations in endometrial cancer","volume":"107","author":"Church","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R52-20250802","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE proofreading mutations elicit an antitumor immune response in endometrial cancer","volume":"21","author":"van Gool","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R53-20250802","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1541-7786.MCR-18-1178","article-title":"Multiclonality and marked branched evolution of low-grade endometrioid endometrial carcinoma","volume":"17","author":"Lazo de la Vega","year":"2019","journal-title":"Mol Cancer Res"},{"key":"R54-20250802","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0090-8258(03)00442-6","article-title":"Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT","volume":"91","author":"Rushing","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R55-20250802","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2004.09.035","article-title":"Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT","volume":"98","author":"Raspollini","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R56-20250802","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/modpathol.2013.199","article-title":"Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement","volume":"27","author":"Lee","year":"2014","journal-title":"Mod Pathol"},{"key":"R57-20250802","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/IGC.0b013e3182055c94","article-title":"Kit gene in endometrial carcinoma: an immunohistochemical and mutational analysis","volume":"21","author":"Vandenput","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"R58-20250802","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2004.06.052","article-title":"Expression of imatinib mesylate-targeted kinases in endometrial carcinoma","volume":"95","author":"Slomovitz","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R59-20250802","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00004347-200304000-00006","article-title":"C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance","volume":"22","author":"Scobie","year":"2003","journal-title":"Int J Gynecol Pathol"},{"key":"R60-20250802","doi-asserted-by":"crossref","first-page":"7449","DOI":"10.7314\/APJCP.2015.16.17.7449","article-title":"C-kit mutations in endometrial cancer: Correlation with tumor histologic type","volume":"16","author":"Kafshdooz","year":"2015","journal-title":"Asian Pacific J Cancer Prev"},{"key":"R61-20250802","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ng.3602","article-title":"The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis","volume":"48","author":"Gibson","year":"2016","journal-title":"Nat Genet"},{"key":"R62-20250802","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc.2015.12","article-title":"A panoply of errors: polymerase proofreading domain mutations in cancer","volume":"16","author":"Rayner","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R63-20250802","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10555-012-9346-z","article-title":"Discoidin domain receptor tyrosine kinases: new players in cancer progression","volume":"31","author":"Valiathan","year":"2012","journal-title":"Cancer Metastasis Rev"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:03:36Z","timestamp":1754161416000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000798","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,6]]}}}